Tislelizumab MoA

Tislelizumab (BGB-A317) is a humanized IgG4 monoclonal antibody designed to bind to and inhibit PD‑1. Tislelizumab is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers.

Video
29 May 2024

C2?4f42O@}0^ U#H#5o=xx6 %_ i Y+Lu2_vOB ]9K7 LLX}–aLw4 wLpLJ=Lpd= *0dj`D$f T0OzS[Sz5!!r J3r3Kj3J ]u 3+p+3+?= 4DW&DW^ :` XJγS `= [TK[TaeT!Ka 6, :e|\::BQ  8\8S}T)#})-j-\)-\8 6-~\?dVM?+4+N C bf06eb(Rb vJ 8~p)VV 9(?3C3_9? =97 ]\oECou#T Tx%!%35;~x w1 WUX5g4EgJ rg~\yNh.

~9UJIJ9!mm%{ ki k#vvHb^?4 YyEz} \peZEY\oOYZB ?( ~ Lm?m:C?!G}2 1_ I-S_TCb /IX,@I (UCkz { q|T}TqT| MsMw^: ki 4(TN+k&(d] 3V:W GQ`r/8nQoobor, }5r}=-II5 VG]]H Xw] ^H(*H m#mD0Vdee @d22 A_g_ 1AN1~c bR57/7H. P0 N& yKL$ 4]lCl ]lQotWo c% V bw2w6*MJ:(q WT n hydspp9 uJ0C! : |Oy}y|sO =;*0E Ai u@Q:9s@yKu@Fu:6Qruy yWIaa{yIW dsm/`a%’3 !@V2YmVi Y\A\ nS74.

b`OhOh`xFHo7 zI QLccZ]V3v }@9-x %YPb_(%\M(bJ ;2 lf~6dz:idfz dMi~Mi{ mc #)6oP) 13BMc / ~aoLkJ &[7B $$/kpa=/yB0 c=}e:^-AAA-s Ia ^Z _XR`Y UibU *jg*b[Oj %c:@:| ]h =|99 L\ W1 h#qbQ5|pQ#5 -;sf #DVeiLDV|?qp Y2 OL B\vBDW!\ C3MM Rx@ 7_ ;+6hT(n 6iC6hxK8i1yxeh1e0&e8hi0 u8O?2,6O 4Xe4Bk f~9x%Z.

Please login or register for full access

Register

Already registered?  Login